Augmedix, Inc.

NasdaqCM:AUGX Stok Raporu

Piyasa değeri: US$116.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Augmedix Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Augmedix's earnings are forecast to decline at 0.9% per annum while its annual revenue is expected to grow at 20.6% per year. EPS is expected to grow by 2.6% per annum.

Anahtar bilgiler

-0.9%

Kazanç büyüme oranı

2.6%

EPS büyüme oranı

Healthcare Services kazanç büyümesi30.6%
Gelir büyüme oranı20.6%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme02 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Augmedix, Inc. (NASDAQ:AUGX) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jun 19
Augmedix, Inc. (NASDAQ:AUGX) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Is Augmedix, Inc. (NASDAQ:AUGX) Trading At A 40% Discount?

May 21
Is Augmedix, Inc. (NASDAQ:AUGX) Trading At A 40% Discount?

Augmedix, Inc. (NASDAQ:AUGX) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Apr 25
Augmedix, Inc. (NASDAQ:AUGX) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-Reward

Mar 24

Augmedix, Inc. (NASDAQ:AUGX) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Nov 09
Augmedix, Inc. (NASDAQ:AUGX) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Augmedix reports Q2 results

Aug 08

Augmedix: A Splendid Long-Term Investing Opportunity

Jan 21

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:AUGX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202569-25N/AN/A2
12/31/202453-30N/AN/A2
6/30/202452-24-18-15N/A
3/31/202449-20-21-17N/A
12/31/202345-19-19-15N/A
9/30/202341-20-21-19N/A
6/30/202337-21-22-20N/A
3/31/202334-24-20-19N/A
12/31/202231-24-18-17N/A
9/30/202229-24-19-18N/A
6/30/202227-21-21-20N/A
3/31/202224-19-18-17N/A
12/31/202122-17-19-19N/A
9/30/202120-16-18-17N/A
6/30/202119-17-14-14N/A
3/31/202117-16-15-14N/A
12/31/202016-16-15-14N/A
9/30/202016-15-16-15N/A
6/30/202015-18-18-17N/A
3/31/202015-19-18-17N/A
12/31/201914-18-15-15N/A
12/31/201811-24-20-20N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AUGX is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: AUGX is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: AUGX is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: AUGX's revenue (20.6% per year) is forecast to grow faster than the US market (8.7% per year).

Yüksek Büyüme Geliri: AUGX's revenue (20.6% per year) is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if AUGX's Return on Equity is forecast to be high in 3 years time

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y